Showing results (271-280 of 317) with videos related to
Sort By:
Pageof 32
Journal of Hepatology|June 11, 2018
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, et al.Molecular Metabolism|November 1, 2019
miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver diseasePablo Fernández-Tussy, David Fernández-Ramos, Fernando Lopitz-Otsoa, et al.Cell Death & Disease|September 22, 2018
MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosisDavid Fernández-Ramos, Pablo Fernández-Tussy, Fernando Lopitz-Otsoa, et al.JHEP Reports : Innovation in Hepatology|May 17, 2021
Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injuryPaula Iruzubieta, Naroa Goikoetxea-Usandizaga, Lucía Barbier-Torres, et al.Alimentary Pharmacology & Therapeutics|June 3, 2025
Occurrence and Management of Opportunistic Infections in Patients With Autoimmune Hepatitis: A Spanish Multicentre StudyMaría Del Barrio, Elena Ferreiro, Elena Gómez, et al.Science Advances|October 22, 2025
Metabolic dysfunction-associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapyTeresa Cardoso Delgado, Celia Martín-Cuevas, Ana C Sánchez Hidalgo, et al.Liver International : Official Journal of the International Association for the Study of the Liver|April 25, 2021
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjectsJavier Ampuero, Rocío Aller, Rocío Gallego-Durán, et al.Nature Communications|December 14, 2017
The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injuryLucía Barbier-Torres, Paula Iruzubieta, David Fernández-Ramos, et al.Gastroenterologia Y Hepatologia|April 11, 2018
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guidelineRocío Aller, Conrado Fernández-Rodríguez, Oreste Lo Iacono, et al.Journal of Gastroenterology|April 15, 2024
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosisJavier Ampuero, Rocío Aller, Rocío Gallego-Durán, et al.Pageof 32